spacer
home > ict > summer 2016 > new fda guidance: impact on clinical safety data
PUBLICATIONS

 

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

spacer

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

 
News and Press Releases

GlycoSeLect and IonDx Inc., Collaborating on High-throughput Glycoprotein Analyses

GlycoSeLect Ltd and IonDx Inc., are actively engaged in a research collaboration to evaluate the use of Recombinant Prokaryotic Lectins RPLs and IonDx’s Ion Mobility Spectrometry technology as a new way to screen glycoproteins rapidly. “GlycoSeLect’s glycan specific lectins provide a high degree of specificity that will improve detection, monitoring and profiling of glycosylation within a wide range of biotherapeutics. Hence, we are excited to join GlycoSeLect and apply our ion mobility technology to all phases of biotherapeutic production and help manufacturers streamline this analytical bottleneck”, said Ms. Ananya Dubey Kelsoe, Executive Director of Business and Corporate Development at IonDx Inc.,
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement